US EditionMaine dispensary reacts to federal marijuana reclassification
The reclassification is expected to improve research access and banking options for dispensaries, while enabling federal tax deductions, advocates say.
- Last week, President Donald Trump signed an executive order to reclassify marijuana from Schedule I to Schedule III, directing the U.S. Attorney General to speed a process begun in May 2024.
- The order aims to expand medical access for people with chronic pain or illness and to increase research, addressing research barriers caused by Schedule I classification.
- Kristin Pettingill, owner of Evergreen Cannabis, said `We have never been treated like a small business. And it's just so exciting that finally we can have some of the same benefits that other small businesses do` and expects new federal tax deductions.
- The Drug Enforcement Administration is expected to move quickly under the order, which aims to accelerate rescheduling but does not immediately reclassify cannabis.
- Industry leaders say the change brings cautious optimism and new uncertainties as the order does not legalize cannabis federally, raising fears it could enable 'big pharma' to reshape Maine's craft market under unclear FDA oversight.
12 Articles
12 Articles
Weatherford Democrat
Trump’s Marijuana Schedule III Order Launches a Federally Regulated Healthcare Sector
MMJ's position is further fortified by its FDA Orphan Drug Designations for the treatment of Huntington's Disease. These designations are awarded to drugs intended for the safe and effective treatment of rare diseases and provide MMJ with critical incentives, including:…
What the reclassification of marijuana in TN means
MEMPHIS, Tenn. -- State officials are weighing in following the major shift in federal drug policy that reclassifies marijuana from a Schedule 1 to a Schedule 3 drug, placing it in the same category as Tylenol with codeine and testosterone. Marijuana was once a Schedule 1 drug in the same category as heroin and ecstasy, [...]
Central Maine News
Maine’s cannabis industry has mixed feelings over federal drug reclassification
Industry members are cautiously optimistic that rescheduling marijuana to a lower tier is one step closer to full legalization, but the fear of a 'Big Pharma' or federal takeover looms large.
Coverage Details
Bias Distribution
- 50% of the sources lean Left, 50% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
